{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/delirium/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"29c67640-566b-5fa4-8966-5b08ca667756","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field c6988384-522b-4ad7-90da-6165348f9770 --><h2>Update</h2><!-- end field c6988384-522b-4ad7-90da-6165348f9770 -->","summary":null,"htmlStringContent":"<!-- begin item ee12f493-d424-4cb4-92a3-4e1df56cec62 --><!-- end item ee12f493-d424-4cb4-92a3-4e1df56cec62 -->","topic":{"id":"6b89f111-d1d1-510e-8846-71e15c389f06","topicId":"64430de8-33e7-409d-b433-725a712a6f41","topicName":"Delirium","slug":"delirium","lastRevised":"Last revised in April 2020","chapters":[{"id":"0455d257-6ef6-5e50-9dc0-21780666b8e7","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a71db69b-5a97-544a-a806-ec82704f3907","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"58e84228-4844-5721-859b-91d58faa7eb6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"999affe9-788e-52a9-83c8-ad933103eeb5","slug":"changes","fullItemName":"Changes"},{"id":"29c67640-566b-5fa4-8966-5b08ca667756","slug":"update","fullItemName":"Update"}]},{"id":"6dddaa0e-c24c-5f4e-8044-6a3229f859df","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"7e8bf385-fd9a-544a-bc9d-375555c17ab0","slug":"goals","fullItemName":"Goals"},{"id":"8f18311c-4fad-5969-8a94-addcca05fb64","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b45b0c3d-03c0-5300-b0c4-62ccd106e229","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7b7d4906-4705-52ba-a39f-ecfb7c5d1e98","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"331ceb18-88fc-530e-aa48-bae28dde9901","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"558ba6d3-06ab-5370-b6b7-09548f2c3c8e","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"b6e24e45-958a-5052-800a-ef5c6f140719","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2b925b35-d493-5d01-bb58-9f18c37e1357","slug":"definition","fullItemName":"Definition"},{"id":"27bd26a5-66e1-5d51-a992-7e06e6a3cdfa","slug":"predisposing-factors","fullItemName":"Predisposing factors"},{"id":"c3582ffa-e505-5580-a3fa-f6a04f0938cc","slug":"precipitating-factors","fullItemName":"Precipitating factors"},{"id":"44402d85-ef9c-562b-ad2c-e99c0d8c60a7","slug":"prevalence","fullItemName":"Prevalence"},{"id":"799dcaa5-4683-5bf0-a9d7-dfc860ab7c81","slug":"complications","fullItemName":"Complications"},{"id":"ca4b25bd-2486-55a7-92c0-c39322caa272","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"993580f3-4201-5dd5-8a6d-f64de509d328","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"3f7d0746-b45f-5f52-8e49-7effac5e3547","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"f84af6b7-85fc-56aa-9554-29d1231a7fd1","slug":"assessment","fullItemName":"Assessment"},{"id":"cc3618cd-d41e-5719-939a-78ed0be305e4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"9d04a09f-9612-570d-aeb7-c0121bda09c4","fullItemName":"Management","slug":"management","subChapters":[{"id":"81f2aa66-ed46-54f0-80b5-4dfca4afb344","slug":"management","fullItemName":"Scenario: Management"},{"id":"58bb812f-7b3c-57be-aab1-8ae228aff1d1","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"769a3265-9e21-5508-b937-bf6aa4a8f378","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"fa09afb1-cc68-5f68-afbe-7486c91a5ed4","slug":"haloperidol","fullItemName":"Haloperidol"},{"id":"4faac93d-8b62-5294-933f-214a1155f283","slug":"lorazepam","fullItemName":"Lorazepam"},{"id":"c02516c6-89cb-5dc3-99db-17f261f5f80e","slug":"levomepromazine","fullItemName":"Levomepromazine"}]},{"id":"cd438911-3d3a-51dd-8455-3e41c260dd60","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"cec2028c-5183-50fb-9bb7-f20aea64a152","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a5323429-af72-5d8b-a251-0715c1a15bba","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"26c6273a-60c7-5b9a-b49f-9f9fbb623941","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b70aed75-14ce-57f4-b2b0-474fa4480d56","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c5faba8c-4118-59d9-af20-8c8d52a89eb2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"71e02a81-885f-515f-8852-109bc9b5580f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"51d66a08-1fc6-5593-8764-c9d4e547d827","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"58e84228-4844-5721-859b-91d58faa7eb6","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"cf71a737-a50b-5dbe-875b-16975474c738","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field 162bc4b1-3fc0-4400-8bd2-9f15b36b908c --><h3>New evidence</h3><!-- end field 162bc4b1-3fc0-4400-8bd2-9f15b36b908c -->","summary":null,"htmlStringContent":"<!-- begin item c03a5af1-7240-4a97-9cd5-7888a6cdfda3 --><!-- begin field 3aee0d67-f997-41db-a3fe-a35b06338a1b --><h3>Evidence-based guidelines</h3><!-- end field 3aee0d67-f997-41db-a3fe-a35b06338a1b --><!-- begin field 18018ee6-5544-4c88-b0f3-f0dda8cec3ee --><ul><li>SIGN (2019) <em>Risk reduction and management of delirium</em>. Scottish Intercollegiate Guidelines Network. <a href=\"https://www.sign.ac.uk/\" data-hyperlink-id=\"87eb2f0b-9073-42ad-9748-aa3f00e2b6bc\">www.sign.ac.uk</a> [<a href=\"https://www.sign.ac.uk/sign-157-delirium.html\" data-hyperlink-id=\"49ff8700-cd5b-4af5-a9b7-aa3f00e2b6ec\">Free Full-text</a>]</li></ul><!-- end field 18018ee6-5544-4c88-b0f3-f0dda8cec3ee --><!-- begin field 794e8734-4b80-44a5-8aaf-40c7b27fc871 --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 794e8734-4b80-44a5-8aaf-40c7b27fc871 --><!-- begin field cc190399-d9f7-49f9-9388-eec77bb58f1e --><p>No new relevant HTAs published since 1 October 2016.</p><!-- end field cc190399-d9f7-49f9-9388-eec77bb58f1e --><!-- begin field 1d6c93fe-2596-45c5-ba59-31545422a3ae --><h3>Economic Appraisals</h3><!-- end field 1d6c93fe-2596-45c5-ba59-31545422a3ae --><!-- begin field 90e41860-1300-44f9-b6bd-7db56d40a8af --><ul><li>Finucane, A.M., Jones, L., Leurent, B. et al. (2020) Drug therapy for delirium in terminally ill adults. <a href=\"https://www.cochranelibrary.com/\" data-hyperlink-id=\"3e444a12-bab1-4119-a01f-ac1e00b88939\">www.cochranelibrary.com</a> [<a href=\"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004770.pub3/full\" data-hyperlink-id=\"091ebef9-8520-4203-b624-ac1e00b88a13\">Free Full-text</a>]</li></ul><!-- end field 90e41860-1300-44f9-b6bd-7db56d40a8af --><!-- begin field 912b00d6-815f-46a3-9f4d-43caf1d0d41f --><h3>Systematic reviews and meta-analyses</h3><!-- end field 912b00d6-815f-46a3-9f4d-43caf1d0d41f --><!-- begin field 73b52342-9115-4bf0-8a76-d7ac3d89261f --><p>No new relevant systematic reviews or meta-analysis published since 1 October 2016.</p><!-- end field 73b52342-9115-4bf0-8a76-d7ac3d89261f --><!-- begin field 43cf4fd7-da5b-4dc7-bddc-34e20eb6aaca --><h3>Primary evidence</h3><!-- end field 43cf4fd7-da5b-4dc7-bddc-34e20eb6aaca --><!-- begin field e22aa769-2210-4604-bd64-5d9affac52d5 --><p>No new randomized controlled trials published in the major journals since 1 October 2016.</p><!-- end field e22aa769-2210-4604-bd64-5d9affac52d5 --><!-- end item c03a5af1-7240-4a97-9cd5-7888a6cdfda3 -->","subChapters":[]},{"id":"18e0fb6a-a2d7-5aed-9f4a-479e9c9619d9","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field f3900d7c-b168-4d6b-99b6-7fcf6635cd5f --><h3>New policies</h3><!-- end field f3900d7c-b168-4d6b-99b6-7fcf6635cd5f -->","summary":null,"htmlStringContent":"<!-- begin item fa35ff8b-f9cb-4c27-9b7c-9caf0612ba7e --><!-- begin field 135062db-04eb-4832-85cf-23f61b87dd09 --><p>No new national policies or guidelines published since 1 October 2016.</p><!-- end field 135062db-04eb-4832-85cf-23f61b87dd09 --><!-- end item fa35ff8b-f9cb-4c27-9b7c-9caf0612ba7e -->","subChapters":[]},{"id":"9e2e09aa-13e0-5eec-8fb1-24ccae9112e6","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field a2bf9b92-97aa-43dc-9cfe-84c65e8afe62 --><h3>New safety alerts</h3><!-- end field a2bf9b92-97aa-43dc-9cfe-84c65e8afe62 -->","summary":null,"htmlStringContent":"<!-- begin item 8c3c18ec-5f02-49ab-a840-bb1fe1df6b75 --><!-- begin field ada59a6e-335e-4a7b-b075-7c2a516596f9 --><p>No new safety alerts published since 1 October 2016.</p><!-- end field ada59a6e-335e-4a7b-b075-7c2a516596f9 --><!-- end item 8c3c18ec-5f02-49ab-a840-bb1fe1df6b75 -->","subChapters":[]},{"id":"64404d9c-7489-5f05-b05c-14a33e0c2cca","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field 1275a161-3a31-4770-b72c-2aa053a14c75 --><h3>Changes in product availability</h3><!-- end field 1275a161-3a31-4770-b72c-2aa053a14c75 -->","summary":null,"htmlStringContent":"<!-- begin item 390abc86-98f2-4cbc-a4fe-90875223cc60 --><!-- begin field 3a0dac38-6518-4d6a-87ec-922545473a26 --><p>No changes in product availability since 1 October 2016.</p><!-- end field 3a0dac38-6518-4d6a-87ec-922545473a26 --><!-- end item 390abc86-98f2-4cbc-a4fe-90875223cc60 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}